Media stories about XOMA (NASDAQ:XOMA) have been trending somewhat positive on Friday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XOMA earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.2387003018044 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of XOMA stock traded down $1.59 during trading hours on Friday, hitting $15.82. The company’s stock had a trading volume of 2,214 shares, compared to its average volume of 144,604. XOMA has a 1-year low of $7.38 and a 1-year high of $37.25. The firm has a market capitalization of $154.57 million, a P/E ratio of 16.33 and a beta of 2.64. The company has a quick ratio of 12.46, a current ratio of 12.46 and a debt-to-equity ratio of 3.06.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). XOMA had a return on equity of 379.39% and a net margin of 43.55%. The business had revenue of $2.26 million during the quarter, compared to analyst estimates of $4.57 million. research analysts expect that XOMA will post -0.94 EPS for the current fiscal year.

Several research firms have recently issued reports on XOMA. TheStreet raised shares of XOMA from a “d” rating to a “c-” rating in a research report on Tuesday, June 12th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of XOMA in a research report on Wednesday, August 8th. HC Wainwright set a $49.00 price objective on shares of XOMA and gave the stock a “buy” rating in a research report on Thursday, May 10th. S&P Equity Research dropped their price objective on shares of XOMA from $18.74 to $16.26 in a research report on Tuesday. Finally, Zacks Investment Research lowered shares of XOMA from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $31.32.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Recommended Story: Google Finance Portfolio Workaround

Insider Buying and Selling by Quarter for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.